» Articles » PMID: 28858536

Serotonin and Brain Function: a Tale of Two Receptors

Overview
Publisher Sage Publications
Specialty Pharmacology
Date 2017 Sep 1
PMID 28858536
Citations 237
Authors
Affiliations
Soon will be listed here.
Abstract

Previous attempts to identify a unified theory of brain serotonin function have largely failed to achieve consensus. In this present synthesis, we integrate previous perspectives with new and older data to create a novel bipartite model centred on the view that serotonin neurotransmission enhances two distinct adaptive responses to adversity, mediated in large part by its two most prevalent and researched brain receptors: the 5-HT1A and 5-HT2A receptors. We propose that passive coping (i.e. tolerating a source of stress) is mediated by postsynaptic 5-HT1AR signalling and characterised by stress moderation. Conversely, we argue that active coping (i.e. actively addressing a source of stress) is mediated by 5-HT2AR signalling and characterised by enhanced plasticity (defined as capacity for change). We propose that 5-HT1AR-mediated stress moderation may be the brain's default response to adversity but that an improved ability to change one's situation and/or relationship to it via 5-HT2AR-mediated plasticity may also be important - and increasingly so as the level of adversity reaches a critical point. We propose that the 5-HT1AR pathway is enhanced by conventional 5-HT reuptake blocking antidepressants such as the selective serotonin reuptake inhibitors (SSRIs), whereas the 5-HT2AR pathway is enhanced by 5-HT2AR-agonist psychedelics. This bipartite model purports to explain how different drugs (SSRIs and psychedelics) that modulate the serotonergic system in different ways, can achieve complementary adaptive and potentially therapeutic outcomes.

Citing Articles

Reduction of Prostate Cancer Risk: Role of Frequent Ejaculation-Associated Mechanisms.

Hassan M, Flanagan T, Eshaq A, Altamimi O, Altalag H, Alsharif M Cancers (Basel). 2025; 17(5).

PMID: 40075690 PMC: 11898507. DOI: 10.3390/cancers17050843.


Societal perspectives on psychedelics use in clinical context: Development of Concerns and Openness towards Psychedelic Scale (COPS).

Holas P, Kaminska J, Zajenkowski M Dialogues Clin Neurosci. 2025; 27(1):11-21.

PMID: 40051051 PMC: 11892042. DOI: 10.1080/19585969.2025.2470426.


A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions.

Brennan W, Kelman A, Belser A Psychedelic Med (New Rochelle). 2025; 1(4):218-229.

PMID: 40046864 PMC: 11658666. DOI: 10.1089/psymed.2023.0007.


Psychophysiological and psychological responses of touching plant behavior by tactile stimulation according to the foliage type.

Kim S, Park S PLoS One. 2025; 20(2):e0316660.

PMID: 40019881 PMC: 11870367. DOI: 10.1371/journal.pone.0316660.


Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications.

Weiss F, Magnesa A, Gambini M, Gurrieri R, Annuzzi E, Elefante C Brain Sci. 2025; 15(2).

PMID: 40002450 PMC: 11853016. DOI: 10.3390/brainsci15020117.


References
1.
Carbonaro T, Bradstreet M, Barrett F, MacLean K, Jesse R, Johnson M . Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol. 2016; 30(12):1268-1278. PMC: 5551678. DOI: 10.1177/0269881116662634. View

2.
Griffiths R, Richards W, Johnson M, McCann U, Jesse R . Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008; 22(6):621-32. PMC: 3050654. DOI: 10.1177/0269881108094300. View

3.
Chapman J . The early symptoms of schizophrenia. Br J Psychiatry. 1966; 112(484):225-51. DOI: 10.1192/bjp.112.484.225. View

4.
Carhart-Harris R, Nutt D . Experienced drug users assess the relative harms and benefits of drugs: a web-based survey. J Psychoactive Drugs. 2014; 45(4):322-8. DOI: 10.1080/02791072.2013.825034. View

5.
Ott U, Reuter M, Hennig J, Vaitl D . Evidence for a common biological basis of the Absorption trait, hallucinogen effects, and positive symptoms: epistasis between 5-HT2a and COMT polymorphisms. Am J Med Genet B Neuropsychiatr Genet. 2005; 137B(1):29-32. DOI: 10.1002/ajmg.b.30197. View